» Articles » PMID: 33964962

RFX1: a Promising Therapeutic Arsenal Against Cancer

Overview
Journal Cancer Cell Int
Publisher Biomed Central
Date 2021 May 9
PMID 33964962
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Regulatory factor X1 (RFX1) is an evolutionary conserved transcriptional factor that influences a wide range of cellular processes such as cell cycle, cell proliferation, differentiation, and apoptosis, by regulating a number of target genes that are involved in such processes. On a closer look, these target genes also play a key role in tumorigenesis and associated events. Such observations paved the way for further studies evaluating the role of RFX1 in cancer. These studies were indispensable due to the failure of conventional chemotherapeutic drugs to target key cellular hallmarks such as cancer stemness, cellular plasticity, enhanced drug efflux, de-regulated DNA repair machinery, and altered pathways evading apoptosis. In this review, we compile significant evidence for the tumor-suppressive activities of RFX1 while also analyzing its oncogenic potential in some cancers. RFX1 induction decreased cellular proliferation, modulated the immune system, induced apoptosis, reduced chemoresistance, and sensitized cancer stem cells for chemotherapy. Thus, our review discusses the pleiotropic function of RFX1 in multitudinous gene regulations, decisive protein-protein interactions, and also its role in regulating key cell signaling events in cancer. Elucidation of these regulatory mechanisms can be further utilized for RFX1 targeted therapy.

Citing Articles

RBM39 promotes hepatocarcinogenesis by regulating RFX1's alternative splicing and subsequent activation of integrin signaling pathway.

Zhang B, Zhou Y, Xu X, Xu G, Wu Z, Wu Q Oncogene. 2025; .

PMID: 40033026 DOI: 10.1038/s41388-025-03327-x.


Proteomics reveals the key transcription-related factors mediating obstructive nephropathy in pediatric patients and mice.

Cao H, Tao Y, Jin R, Li P, Zhou H, Cheng J Ren Fail. 2025; 47(1):2443032.

PMID: 39743726 PMC: 11703465. DOI: 10.1080/0886022X.2024.2443032.


Regulatory factor X1 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by transcriptional regulation of BECN1.

Yang Z, Yuan Y, Niu Y, Zuo D, Liu W, Li K Cell Oncol (Dordr). 2024; .

PMID: 39652303 DOI: 10.1007/s13402-024-01017-6.


Hypoglycemic Agents Increase Regulatory Factor X1 to Inhibit Cancer Cell Behaviour in Human Glioblastoma Cells.

Shan W, Zuo K, Zuo Z J Cell Mol Med. 2024; 28(23):e70260.

PMID: 39636301 PMC: 11619449. DOI: 10.1111/jcmm.70260.


Association Between the rs13306703 and rs8192288 Variants of the Gene and Breast Cancer and an In Silico Analysis of the Variants' Impact.

Gallegos-Arreola M, Garibaldi-Rios A, Magana-Torres M, Figuera L, Gomez-Meda B, Zuniga-Gonzalez G Diseases. 2024; 12(11).

PMID: 39589950 PMC: 11592857. DOI: 10.3390/diseases12110276.


References
1.
Zhao M, Wu X, Zhang Q, Luo S, Liang G, Su Y . RFX1 regulates CD70 and CD11a expression in lupus T cells by recruiting the histone methyltransferase SUV39H1. Arthritis Res Ther. 2011; 12(6):R227. PMC: 3046540. DOI: 10.1186/ar3214. View

2.
Li J, Ding Y, Li A . Identification of COL1A1 and COL1A2 as candidate prognostic factors in gastric cancer. World J Surg Oncol. 2016; 14(1):297. PMC: 5126984. DOI: 10.1186/s12957-016-1056-5. View

3.
Udeshi N, Svinkina T, Mertins P, Kuhn E, Mani D, Qiao J . Refined preparation and use of anti-diglycine remnant (K-ε-GG) antibody enables routine quantification of 10,000s of ubiquitination sites in single proteomics experiments. Mol Cell Proteomics. 2012; 12(3):825-31. PMC: 3591673. DOI: 10.1074/mcp.O112.027094. View

4.
Tamagawa Y, Ishimura N, Uno G, Yuki T, Kazumori H, Ishihara S . Notch signaling pathway and Cdx2 expression in the development of Barrett's esophagus. Lab Invest. 2012; 92(6):896-909. DOI: 10.1038/labinvest.2012.56. View

5.
Chen B, Song G, Liu M, Qian L, Wang L, Gu H . Inhibition of miR-29c promotes proliferation, and inhibits apoptosis and differentiation in P19 embryonic carcinoma cells. Mol Med Rep. 2016; 13(3):2527-35. PMC: 4769000. DOI: 10.3892/mmr.2016.4832. View